Bruno ségui – nathalie andrieu
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy
General presentation of the team
Our team was created in 2011, under the direction of Prof. Thierry Levade. Since 2021, it has been led by Prof. Bruno Ségui and Dr. Nathalie Andrieu-Abadie. It is composed of 26 members, including 3 researchers, 2 assistant professors, 4 professors, 5 engineers/technicians, 2 hospital practitioners, 2 post-doctoral fellows, 5 PhD students and 3 master trainees per year.
Cutaneous melanoma is the leading cause of death among skin cancers. Immune checkpoint inhibitors (ICI) have revolutionised the therapeutic management of patients with advanced cutaneous melanoma. However, only half of patients respond sustainably to ICIs due to primary or adaptive resistance mechanisms. Abnormal lipid profiles are often associated with an altered metabolic phenotype in tumour cells, which is a hallmark of cancer. The scientific activity of our team aims to better understand the molecular mechanisms by which alterations in ceramide metabolism contribute to melanoma progression, immune escape and resistance to ICI in preclinical models of melanoma. Through existing collaborations between researchers and clinicians, our ambition is to transfer our basic scientific findings to the clinic with the aim of identifying new biomarkers to predict response to ICIs and to propose appropriate treatments for patients with advanced melanoma. In addition, our research over the past 5 years has provided the scientific rationale for three clinical trials in 150 patients with advanced melanoma treated with immunotherapy. These trials are under the responsibility of Prof. Nicolas Meyer, oncodermatologist at the IUCT.
Our ultimate goal is to reprogram the metabolism of ceramide to improve therapeutic efficacy.
of our research axis
Role of ceramide metabolism in epidermal homeostasis and melanoma progression
Associate investigators : Joëlle Riond et Frédérique Sabourdy
Interconnections between TNF signalling and ceramide metabolism in melanoma
Associate investigators : Nathalie Andrieu, Céline Colacios, Anne Montfort
Reprogramming ceramide metabolism to overcome resistance to immunotherapies
Céline Colacios, Anne Montfort
Associate investigators : Nathalie Andrieu, Thierry Levade, Laurence Nieto
Metabolites and enzymes of ceramide metabolism as biomarkers of resistance to immunotherapies?
Associate investigators : Nathalie Andrieu, Céline Colacios, Anne Montfort et Bruno Ségui
TNF, a new target for immunotherapy ?
Associate investigators : Anne Montfort et Bruno Ségui
Partnerships & funding
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?